Dr. Burke on a Study Investigating Obinutuzumab in Large B-Cell Lymphoma

John M. Burke, MD
Published: Monday, Dec 05, 2016

John M. Burke, MD, discusses the GOYA study, a phase III study investigating obinutuzumab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma. Burke discussed the study during the American Society of Hematology (ASH) Annual Meeting.
 
In the lab, obinutuzumab (Gazyva) looks to have different properties that could make it, in theory, more effective that rituximab (Rituxan) in treating malignancies that express CD20, like large-cell lymphoma, Burke says.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x